Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs

European Neuropsychopharmacology

Volumn 23, Issue 3, 2013, Pages 205-211

  Manu, Peter ^a,b,c   Correll, Christoph U ^a,b,d   Wampers, Martien ^e   Van Winkel, Ruud ^e,f   Yu, Weiping ^e   Mitchell, Alex J ^g   De Hert, Marc ^e  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c TRANSILVANIA UNIVERSITY OF BRASOV   (Romania)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Antipsychotic drugs; Hemoglobin A1c; Impaired fasting glucose; Prediabetes

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; METABOLIC PARAMETERS; PRIORITY JOURNAL; SIDE EFFECT; WAIST CIRCUMFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; MOOD DISORDERS; PERSONALITY DISORDERS; PHENOTYPE; PREDIABETIC STATE; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84875253186     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.05.002     Document Type: Article

References (44)

1. Aas I.H. Guidelines for rating global assessment of functioning (GAF). Arch. Gen. Psychiatry 2011, 10:2.
2. Abdul-Ghani M.A., Abdul-Ghani T., Muller G., Bergmann A., Fischer S., Bornstein S., Defronzo R.A., Schwarz P. Role of glycated hemoglobin in the prediction of future risk of T2DM. J. Clin. Endocrinol. Metab. 2011, 96(8):2596-2600. (Epub 2011 June 6).
3. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antiosychotic drugs and obesity and diabetes. J. Clin. Psychiatry 2004, 65:267-272.
4. American Diabetes Association Standards of medical care in diabetes - 2010. Diabetes Care 2010, 33(suppl 1):S11-S61.
5. Bennett C.M., Guo M., Dharmage S.C. HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review. Diabet Med. 2007, 24(4):333-343. (Epub 2007 March 15).
6. Bersoux S., Cook C.B., Wu Q., Burritt M.F., Hernandez J.S., Verona P.M., Larson M.H., Larosa C.S. Hemoglobin A1c testing alone does not sufficiently identify patients with prediabetes. Am. J. Clin. Pathol. 2011, 135(5):674-677.
7. Bond D.J., Kauer-Sant'Anna M., Lam R.W., Yatham L.N. Weight gain, obesity and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). J. Affect. Disord. 2010, 124:108-117.
8. Borai A., Livingstone C., Abdelaal F., Bawazeer A., Keti V., Ferns G. The relationship between glycosylated haemoglobin (HbA1c) and measures of insulin resistance across a range of glucose tolerance. Scand. J. Clin. Lab. Invest. 2011, 7:168-172.
9. Choi S.H., Kim T.H., Lim S., Park K.S., Jang H.C., Cho N.H. Hemoglobin A1c as a diagnostic tool for diabetes screening and new-onset diabetes prediction: a 6-year community-based prospective study. Diabetes Care 2011, 34:944-949.
10. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008, 10(7):788-797.
11. Correll C.U., Kane J.M., Manu P. Identification of high-risk coronary heart disease patients receiving atypical antipsychotics: single low-density lipoprotein cholesterol threshold or complex national standard?. J. Clin. Psychiatry 2008, 69:578-583.
12. Correll C.U., Lencz T., Malhotra A.K. Antipsychotic drugs and obesity. Trends Mol. Med. 2011, 17:97-107.
13. De Hert M., Vancampfort D., Correll C.U., Mercken V., Peuskens J., Sweers K., van Winkel R., Mitchell A.J. A systematic evaluation and comparison of the guidelines for screening and monitoring of cardiometabolic risk in people with schizophrenia. Br. J. Psychiatry 2011, 199:99-105.
14. De Hert M., Detraux J., van Winkel R., Yu W., Correll C.U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 2011, 18. (Epub ahead of print).
15. De Hert M., van Winkel R., Van Eyck D., et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a crosssectional study. Clin. Pract. Epidemol. Ment. Health 2006, 2:14.
16. Faerch K., Borch-Johnson K., Holst J.J., Vaag A. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?. Diabetologia 2009, 52(9):1714-1723. (Epub 2009 July 10).
17. 1c determination in diagnosis or screening of early diabetic states. Metab. Clin. Exp. 2011, 60:86-91.
18. Grundy S.M., Brewer H.B., Cleeman J.I., et al. American Heart Association/National heart, Lung and Blood Institute. Definition of metabolic syndrome. Circulation 2004, 109:408-433.
19. Heianza Y., Hara S., Arase Y., Saito K., Fujiwara K., Kodama S., Hsieh S.D., Mori Y., Shimano H., Yamada N., Kosaka K., Sone H. HbA1c 5.7-6.4% and impaired fasting plasma glucose for the diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet 2011, 378:147-155.
20. Herman W.H., Fajans S.S. Hemoglobin A1c for the diagnosis of diabetes: practical considerations. Pol. Arch. Med. Wewn 2010, 120(1-2):37-40.
21. James C., Bullard K.M., Rolka D.B., Geiss L.S., Williams D.E., Cowie C.C., Albright A., Gregg E.W. Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes Care 2011, 34(2):387-391.
22. Kessing L.V., Thomsen A.F., Mogensen U.B., Andersen P.K. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br. J. Psychiatry 2010, 197:266-271.
23. Lapolla A., Mosca A., Fedele D. The general use of glycated haemoglobin for the diagnosis of diabetes and other categories of glucose intolerance: still a long way to go. Nutr. Metab. Cardiovasc. Dis. 2011, 21:467-475.
24. Likhari T., Gama R. Ethnic differences in glycated haemoglobin between white subjects and those of South Asian origin with normal glucose tolerance. J. Clin. Pathol. 2010, 63(3):278-280.
25. Lin E.J., Lee N.J., Slack K., Karl T., Duffy L., O'brien E., Matsumoto I., Dedova I., Herzog H., Sainsbury A. Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. Neuropharmacology 2006, 51(7-8):1129-1136. (Epub 2006 August 21).
26. Lipska K.J., De Rekeneire N., Van Ness P.H., et al. Identifying dysglycemic states in older adults: implications of the emerging use of hemoglobin A1c. J. Clin. Endocrinol. Metab. 2010, 22. (Epub ahead of print).
27. Lorenzo C., Wagenknecht L.E., Hanley A.J.G., Rewers M.J., Karter A.J., Haffner S.M. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors. Diabetes Care 2010, 33(9).
28. Manu P., Correll C.U., van Winkel R., Wampers M., De Hert M. Prediabetes in patients treated with antipsychotic drugs. J. Clin. Psychiatry 2012, 73:460-466.
29. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985, 28:412-419.
30. Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a PRISMA Meta-analysis. Schizophr. Bull 2012.
31. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
32. Nilsson P.M., Gudbjomsdottir S., Eliasson B., Cederholm J. Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes-data from the National diabetes Register in Sweden. Diabetes Metab. 2004, 30(3):261-268.
33. Notsu Y., Nabika T., Shibata H., Nagai A., Shiwaku K., Masuda J. HOMA-IR and related clinical parameters. Rinsho Biori 2007, 55:737-742.
34. Pani L.N., Korenda L., Meigs J.B., Driver C., Chamany S., Fox C.S., Sullivan L., D'Agostino R.B., Nathan D.M. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care 2008, 31(10):1991-1996. (Epub 2008 July 15).
35. Rabinowitz J., Mehnert A., Eerdekens M. To what extent do the PANSS and CGI-S overlap?. J. Clin. Psychopharmacol. 2006, 26:303-307.
36. Schottker D., Raum E., Rothenbacher D., Muller H., Brenner H. Prognostic value of hemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening. Eur. J. Epidemiol. 2011, 26:779-787.
37. Selvin E., Zhu H., Brancati F.L. Elevagted A1C in adults without a history of diabetes in the U.S. Diabetes Care 2009, 32(5):828-833. (Epub 2009 February 5).
38. Smith G.C., Vickers M.H., Cognard E., Shepherd P.R. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr. Res. 2009, 115:30-40.
39. Smith M., Hopkins D., Peveler R.C., Holt R.I., Woodward M., Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry 2008, 192:406-411.
40. Succurro E., Marini M.A., Arturi F., Grembiale A., Fiorentino T.V., Andreozzi F., Sciacqua A., Lauro R., Hribal M.L., Perticone F., Sesti G. Usefulness of hemoglobin A1c as a criterion define the metabolic syndrome in a cohort of Italian nondiabetic white subjects. Am. J. Cardiol. 2012, (Epub ahead of print).
41. van der Zwaal E.M., Merkestein M., Lam Y.K., Brans M.A., Luijendijk M.C., Bok L.I., Verheij E.R., la Fleur S.E., Adan R.A. The acute effects of olanzapine on ghrelin secretion, CCK sensitivity, meal size, locomotor activity and body temperature. Int. J. Obes. (Lond) 2011, 10(1-8). (Epub ahead of print).
42. van Winkel R., De Hert M., Wampers M., et al. Major changes in glucose metabolism, including new onset diabetes, within 3 months after initiation or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 2008, 69:472-479.
43. van't Riet E., Rijkelijkhulzen J.M., Kostense P.J., Nijpels G., Dekker J.M. Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study. Diabetes Care 2010, 33(1):60-66. (Epub 2009 October 6).
44. Yood M.U., DeLorenze G., Quesenberry C.P., et al. The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study. Pharmacoepidemiol. Drug Saf. 2009, 18:791-799.